Craig Kessler
Hematology & Oncology · Washington, DCNPI 1356340517
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $290,377 of the $449,451 with a category attached, or 64.6%. It is spread thinly across 34 manufacturers, the largest accounting for just 15.8%. Reporting peaked in 2019 at $99,319 and has fallen 62.1% since, to $37,647 in 2025. Among hematology & oncology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $1370.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$71K
- Octapharma USA, Inc.$60K
- Novartis$48K
- Bayer$44K
- Pfizer$37K
- Takeda Pharmaceuticals U.S.A., Inc.$33K
- plus $157K from 28 others
Across 65 payments — averaging $6128.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Diagnostica Stago, Inc$105K
- Octapharma USA, Inc.$88K
- Genentech, Inc.$58K
- Incyte Corporation$49K
- Bayer$42K
- Regeneron$30K
- plus $26K from 2 others
What the payments were for
- Consulting fees$290,37765%
- Speaking & faculty fees$82,28418%
- Travel & lodging$67,75715%
- Food & beverage$8,7712%
- Education$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $70,842 |
| Octapharma USA, Inc. | 35 | $59,992 |
| Novartis | 21 | $47,880 |
| Bayer | 46 | $43,698 |
| Pfizer | 18 | $37,343 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $32,775 |
| Genentech USA, Inc. | 28 | $25,062 |
| CSL Behring | 14 | $22,914 |
| Regeneron | 20 | $15,385 |
| Sanofi US Services Inc. | 6 | $13,219 |
| Novo Nordisk Health Care AG | 6 | $13,104 |
| Shire North American Group Inc | 15 | $10,862 |
| Spark Therapeutics, Inc. | 6 | $8,532 |
| Diagnostica Stago, Inc | 6 | $7,557 |
| Rigel Pharmaceuticals, Inc. | 7 | $6,253 |
| Dova Pharmaceuticals | 2 | $6,080 |
| Biomarin Pharmaceutical Inc. | 2 | $4,700 |
| Grifols Shared Services North America, Inc. | 2 | $4,188 |
| UCB SA | 1 | $4,140 |
| Aptevo Therapeutics Inc | 4 | $3,414 |
| Incyte Corporation | 10 | $3,381 |
| Novo Nordisk AS | 6 | $3,215 |
| Sanofi | 5 | $3,137 |
| F. Hoffmann-la Roche AG | 1 | $915 |
| Johnson & Johnson | 4 | $284 |
| AstraZeneca | 1 | $250 |
| Bio Products Laboratory USA, Inc. | 1 | $135 |
| HEMA Biologics, LLC | 1 | $38 |
| Exelixis Inc. | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Beone Medicines USA, Inc. | 1 | $28 |
| Sobi, Inc | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUWIQ$43,082
- PROMACTA$37,871
- NovoSeven RT$32,620
- HEMLIBRA$25,509
- Jivi$25,096
- Idelvion$19,997
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$18,770
- HYMPAVZI$12,600
- ADVATE$11,750
- NovoSeven$9,995
- Afstyla$7,152
- DOPTELET$6,080
- Tavalisse$6,077
- ADYNOVATE$5,000
- FEIBA$5,000
- BENEFIX$4,392
- Alphanate$4,188
- IXINITY$3,364
- LUXTURNA$1,450
- Coagadex$135
How this compares
$449,451 in reported general payments places this provider in the 95th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 85 | $1,718,932 |
| BesremiRopeginterferon Alfa-2b-Njft | 29 | $494,204 |
| PegasysPeginterferon Alfa-2a | 65 | $281,059 |
| DopteletAvatrombopag Maleate | 12 | $232,412 |
| PromactaEltrombopag Olamine | 24 | $100,184 |
| EliquisApixaban | 63 | $83,441 |
| Imatinib Mesylate | 24 | $58,424 |
| XareltoRivaroxaban | 25 | $41,466 |
| Enoxaparin Sodium | 16 | $10,710 |
| Anagrelide Hcl | 12 | $5,058 |
| Tranexamic Acid | 38 | $4,454 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $4,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $3,381 | $1,718,93285 claims |
| Dova PharmaceuticalsDoptelet | $6,080 | $232,41212 claims |
| NovartisPromacta | $47,880 | $100,18424 claims |
| PfizerEliquis | $37,343 | $83,44163 claims |
| Johnson & JohnsonXarelto | $284 | $41,46625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
- Faysal HarounWashington$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.